A novel and safe approach for treating cognitive and sleep disorders
Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy (HE) in patients with liver disease, and for the treatment of excessive daytime sleepiness in patients with idiopathic hypersomnia (IH)
Hepatic Encephalopathy is a serious neuropsychiatric and neurocognitive complication in acute and chronic liver disease ranging from minimal to overt Hepatic Encephalopathy, characterized by impaired cognitive and motor functions and with symptoms ranging from disorientation, sedation through coma. Idiopathic hypersomnia (IH) is a severe orphan disease characterized by chronic excessive daytime sleepiness (EDS) despite normal sleep. It is a lifelong debilitating condition with a profound effect on the patients quality of life. There are no approved treatments for IH.
The company's therapy represents a new target class. The lead compound, GR3027, in clinical development for HE and IH, is a GABAA receptor modulating steroid antagonist (GAMSA) designed to antagonize GABAA receptor activation and neuroinhibition by endogenous neuroactive steroids. GR3027 has been shown to restore different types of neurological impairments including cognitive and sleep alternations in experimental models. The drug candidate enters the CNS and reverses the inhibitory effects of the neurosteroid allopregnanolone on brain function in humans. Collectively, these findings strongly implicate that GR3027 is a promising novel treatment for a wide range of cognitive and sleep disorders.
Umecrine Cognition announces first patient included in part D in clinical Phase 2a study with GR3027 in patients with liver cirrhosis and hepatic encephalopathy